

with the responsibilities specified in this MOU. FDA should pay round trip transportation expenses between the United States of America and the United Mexican States and the per diem of the members of the FDA evaluation team while in the United Mexican States.

6. Notify COFEPRIS of NSSP deficiencies and request that COFEPRIS submit, within 30 days, a written Corrective Action Plan to FDA for review and concurrence. If a Plan is not developed within 30 days or if the deficiencies are not corrected in accordance with the Plan, FDA will remove Mexican processors from the ICSSL and/or take other appropriate action to stop Mexican molluscan shellfish from entering the United States of America. In case of a serious public health threat, this 30 day period may be reduced or eliminated. Such action should remain in effect until all NSSP deficiencies have been corrected and FDA has determined that the MSSP is in compliance with the NSSP.
7. Remove individual Mexican processors from the ICSSL when it is determined by FDA or COFEPRIS that a processor is not in compliance with the NSSP or when an imminent health hazard exists with a processor's product.
8. Report any change in responsibility from FDA to another federal authority to COFEPRIS within 30 days of such change.

ARTICLE IV

Technical Information Exchange

The working language for documents exchanged under this MOU should be English. The Participants plan to share expertise, provide assistance, and exchange information. Such mutual cooperation may include, but is not be limited to:

1. Exchanging information concerning proposed and final changes in MSSP operations and procedures including, but not limited to:

- a. methods and procedures for sampling;
- b. methods of analysis;
- c. methods of confirmation;
- d. administrative guidelines, tolerances, specification standards, and nomenclature;
- e. reference standards; and
- f. inspection procedures.